The combination of pamiparib plus TMZ may be most effective in patients with tumor types known to be sensitive to PARP inhibitors (i.e., ovarian cancer, prostate cancer, or breast cancer) with HRD+ status determined using a GIS cutoff of ≥33. This evidence concerns the gene PARP1 and prostate carcinoma.